Lymphangiogenesis in malignant tumours: Does it occur?

Journal of Pathology

Volumn 193, Issue 2, 2001, Pages 143-146

  Clarijs, Ruud ^a   Ruiter, Dirk J ^a   De Waal, Robert M W ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; Carcinoma; Flt 4; Lymphangiogenesis; VEGF C; VEGFR 3

Indexed keywords

5' NUCLEOTIDASE; BIOCHEMICAL MARKER; CD31 ANTIGEN; MEMBRANE PROTEIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULTHOOD; ANGIOGENESIS; ANIMAL TISSUE; CELL PROLIFERATION; CLINICAL PROTOCOL; CONTROLLED STUDY; DIAGNOSTIC VALUE; EDITORIAL; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; ENZYME HISTOCHEMISTRY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH FLOW; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; SOLID TUMOR; STEM CELL; TUMOR VASCULARIZATION; UVEA MELANOMA;

ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, LYMPHATIC; ENDOTHELIUM, VASCULAR; HUMANS; LYMPHATIC SYSTEM; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035150823     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.808     Document Type: Editorial

References (47)

1. What is the evidence that tumors are angiogenesis dependent?
2. Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages
3. Macrophages and angiogenesis
4. Intratumoral microvessel density as a prognostic factor in cancer
5. Molecular biology of cancer: Invasion and metastasis
6. Tumor vascularity is not a prognostic factor for malignant melanoma of the skin
7. Tumour vascularity is not a prognostic factor for cutaneous melanoma
8. Tumor angiogenesis, the p53 antigen, and cervical metastasis in squamous carcinoma of the tongue
9. Thrombomodulin as a marker of vascular and lymphatic tumours
10. Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens - Evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor
11. QBEnd/10: A new immunostain for the routine diagnosis of Kaposi's sarcoma
12. Lack of lymphangiogenesis in human primary cutaneous melanoma. Consequences for the mechanism of lymphatic dissemination
13. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development
14. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3
15. Expression of the vascular endothelial growth factor c receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors
16. Vascular endothelial growth factor receptor-3 in lymphangio-genesis in wound healing
17. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors
18. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer
19. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries. Podoplanin as a specific marker for lymphatic endothelium
20. Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells
21. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis
22. Histochemical localization of 5′-nucleotidase in the lymphatic endothelium
23. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours
24. The histochemical distribution of 5-nucleotidase and unspecific alkaline phosphatase in the testicle of various species and two human seminomas
25. Angiogenesis and tumor growth
26. On tumor (and other) lymphangiogenesis
27. Angiogenesis and tumor growth
28. Vascular permeability factor/vascular endothelial growth factor: An important mediator of angiogenesis in malignancy and inflammation
29. Embryonic lymphangiogenesis
30. Regulation of angiogenesis via vascular endothelial growth factor receptors
31. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema
32. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase
33. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases
34. Vascular endothelial growth factor-related protein: A ligand and specific activator of the tyrosine kinase receptor Flt4
35. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice
36. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development
37. VEGF and VEGF-C: Specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane
38. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors
39. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia
40. Vascular endothelial growth factor-C gene expression in papillary and follicular thyroid carcinomas
41. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis
42. Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa
43. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer
44. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features
45. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)
46. Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis
47. The lymphatic system in human embryos, with consideration of the morphology of the system as a whole